MedTrace Logo

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

NCT02152761 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2020-08-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

Conditions

  • Muscle Wasting (Atrophy) After Hip Fracture Surgery

Interventions

DRUG

bimagrumab

Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.

OTHER

placebo

Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-16
Primary Completion
2018-05-14
Completion
2018-10-25
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Chile
  • Colombia
  • Czechia
  • France
  • Germany
  • Hungary
  • Japan
  • Mexico
  • Russia
  • Spain
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02152761 on ClinicalTrials.gov